Reneo Pharmaceuticals, Inc.
NASDAQ:RPHM
18.2 (USD) • At close October 4, 2024
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Omzet
| 0 | 0 | 0.734 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Kosten van de omzet
| 0.012 | 0.016 | 0.044 | 0.043 | 0.163 | 0.161 | 0.128 | 0.119 | 0.022 | 0.019 | 0.017 | 0.013 | 0.01 | 0.01 | 0 | 0 | 0 | 0 |
Brutowinst
| -0.012 | -0.016 | 0.69 | -0.043 | -0.163 | -0.161 | -0.128 | -0.119 | -0.022 | -0.019 | -0.017 | -0.013 | -0.01 | -0.01 | 0 | 0 | 0 | 0 |
Brutowinstmarge
| 0 | 0 | 0.94 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Onderzoek- en ontwikkelingskosten
| 0.578 | 4.926 | 17.56 | 13.622 | 14.4 | 10.991 | 10.357 | 9.938 | 8.132 | 9.278 | 7.1 | 9.318 | 6.279 | 5.472 | 5.118 | 4.431 | 2.817 | 3.578 |
Algemene en administratieve kosten
| 5.774 | 4.622 | 7.402 | 7.266 | 6.639 | 5.132 | 4.205 | 3.902 | 4.299 | 3.737 | 3.524 | 3.434 | 2.949 | 1.742 | 1.133 | 0.668 | 0.882 | 0.924 |
Verkoop- en marketingkosten
| 0 | 0 | 1.062 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Verkoop-, algemene en administratieve kosten
| 5.774 | 4.622 | 8.464 | 7.266 | 6.639 | 5.132 | 4.205 | 3.902 | 4.299 | 3.737 | 3.524 | 3.434 | 2.949 | 1.742 | 1.133 | 0.668 | 0.882 | 0.924 |
Overige kosten
| 1.003 | 1.138 | 1.452 | 1.692 | 1.508 | 1.016 | 0.962 | 0.833 | 0.119 | -0.021 | 0.017 | 0.017 | 0.012 | 0.002 | -0.002 | 0.005 | 0.012 | 0.071 |
Bedrijfskosten
| 6.352 | 9.548 | 26.024 | 20.888 | 21.039 | 16.123 | 14.562 | 13.84 | 12.431 | 13.015 | 10.624 | 12.752 | 9.228 | 7.214 | 6.251 | 5.099 | 3.699 | 4.502 |
Bedrijfsresultaat
| -6.364 | -9.564 | -26.068 | -20.888 | -21.039 | -16.123 | -14.562 | -13.84 | -12.431 | -13.015 | -10.624 | -12.752 | -9.228 | -7.214 | -6.251 | -5.099 | -3.699 | -4.502 |
Bedrijfsresultaat ratio
| 0 | 0 | -35.515 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Totaal overige inkomsten en kosten netto
| 1.003 | 1.138 | 2.514 | 1.692 | 1.508 | 1.016 | 0.962 | 0.833 | 0.119 | -0.021 | 0.017 | 0.017 | 0.012 | 0.002 | -0.002 | 0.005 | 0.012 | 0.071 |
Inkomen voor belasting
| -5.361 | -8.426 | -23.554 | -19.196 | -19.531 | -15.107 | -13.6 | -13.007 | -12.312 | -13.036 | -10.607 | -12.735 | -9.216 | -7.212 | -6.253 | -5.094 | -3.687 | -4.431 |
Inkomen voor belasting ratio
| 0 | 0 | -32.09 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Belastingkosten
| 0 | -0.027 | 1.059 | -0.043 | -0.08 | -1.016 | -0.962 | -0.833 | 0 | 0.021 | -0.017 | -0.034 | -0.012 | -0.002 | 0.004 | -0.01 | -0.012 | -0.071 |
Nettowinst
| -5.361 | -8.426 | -23.554 | -19.196 | -19.531 | -14.091 | -12.638 | -12.174 | -12.312 | -13.057 | -10.607 | -12.735 | -9.216 | -7.212 | -6.253 | -5.094 | -3.687 | -4.431 |
Nettowinstmarge
| 0 | 0 | -32.09 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
WPA (Winst Per Aandeel)
| -0.16 | -0.25 | -0.7 | -0.57 | -0.65 | -0.56 | -0.52 | -0.5 | -0.5 | -0.53 | -0.43 | -0.52 | -0.43 | -0.3 | -0.26 | -0.65 | -0.47 | -0.57 |
Verwaterde WPA
| -0.16 | -0.25 | -0.7 | -0.57 | -0.65 | -0.56 | -0.52 | -0.5 | -0.5 | -0.53 | -0.43 | -0.52 | -0.43 | -0.3 | -0.26 | -0.65 | -0.47 | -0.57 |
EBITDA
| -6.352 | -9.548 | -26.024 | -20.888 | -20.997 | -16.082 | -14.562 | -13.818 | -12.409 | -12.996 | -10.624 | -12.739 | -9.218 | -7.204 | -6.241 | -5.09 | -3.69 | -4.493 |
EBITDA ratio
| 0 | 0 | -35.455 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |